What Is Feline Infectious Peritonitis (FIP)?
Feline Infectious Peritonitis (FIP) is a fatal disease caused by mutation of the Feline Coronavirus (FCoV). According to a review in the Journal of Feline Medicine and Surgery (Pedersen, 2009), approximately 25–40% of domestic cats carry feline coronavirus, with infection rates in multi-cat environments reaching as high as 80–90%.
However, carrying feline coronavirus does not mean a cat will develop FIP. FIP only develops when the virus mutates within an individual cat and the cat's immune system is unable to effectively control the mutated virus. According to current research, approximately 5–12% of FCoV-infected cats ultimately develop FIP.
FCoV ≠ FIP: The Critical Distinction
This is the most commonly misunderstood aspect of FIP. The two must be clearly separated:
| Aspect | FCoV (Feline Coronavirus) | FIP (Infectious Peritonitis) |
|---|---|---|
| Contagious? | Yes, fecal-oral route (very common) | Almost never cat-to-cat directly |
| Severity | Often asymptomatic or mild diarrhea | Fatal; near 100% mortality untreated |
| What does antibody-positive mean? | Past FCoV exposure (very common) | Cannot diagnose FIP from antibody alone |
| Treatment needed? | Usually no | Immediate treatment required |
In short: FCoV is like a common cold virus; FIP is the rare, fatal complication that occurs when the virus mutates inside a specific cat.
Risk Factors: Who Gets FIP?
The following groups have a significantly elevated risk of developing FIP:
- Kittens (under 2 years old): Immature immune system; the peak age of onset
- Senior cats (10+ years): Declining immunity, the second peak
- Multi-cat households and shelter environments: High FCoV prevalence increases mutation chances
- Purebred cats: Ragdolls, Maine Coons, Bengals, and Birmans show higher incidence (genetic factors)
- Immunosuppressed cats: FeLV+, FIV+, or cats on long-term steroids
- Recent major stress: Moving, surgery, new household members, or spay/neuter can be triggers
FIP Forms: Wet, Dry, Ocular, and Neurological
| Form | Key Features | Progression | Treatment Response |
|---|---|---|---|
| Wet (Effusive) | Fluid in abdominal/thoracic cavity; abdominal distension or breathing difficulty | Faster (weeks) | Faster response |
| Dry (Non-effusive) | Granulomatous lesions in organs; no obvious effusion | Slower (months) | Slower; requires higher dose |
| Ocular | Uveitis, iris color change, anterior chamber flare, anisocoria | Chronic | Higher dose needed to cross blood-eye barrier |
| Neurological | Ataxia, head tilt, seizures, nystagmus | Progressive deterioration | Highest dose to cross blood-brain barrier |
Many cases present as a mix of forms. Ocular and neurological FIP are essentially "dry FIP affecting the eye or central nervous system," and treatment doses must be raised substantially to penetrate these compartments.
Common FIP Symptoms Checklist
FIP symptoms are diverse and non-specific. Any combination below warrants veterinary investigation:
- Persistent fever: Recurring fever (above 39.5°C / 103°F) unresponsive to antibiotics
- Decreased appetite and weight loss: Eating less or refusing food
- Lethargy: Sleepy, hiding, less active
- Abdominal distension (wet form): Ascites with thin limbs
- Difficulty breathing (wet form): Pleural effusion compresses lungs; rapid or open-mouth breathing
- Jaundice: Yellow gums, sclera, or inner ear flaps when liver is affected
- Eye abnormalities (ocular form): Iris color change, anisocoria, anterior chamber haze, third-eyelid prolapse
- Neurological signs (neuro form): Ataxia, head tilt, seizures, behavioral changes
- Lymph node enlargement: Especially mesenteric lymph nodes
- Poor coat condition: Dull, matted fur
Diagnosis: Why FIP Is Hard to Confirm
Definitive diagnosis of FIP in a living animal is notoriously difficult because no single test is 100% confirmatory. According to diagnostic guidelines in the Journal of Feline Medicine and Surgery(Tasker, 2018), veterinarians integrate the following findings:
Blood Work and Biochemistry
- Albumin/globulin ratio (A:G): < 0.4 highly suspicious of FIP; > 0.8 less likely
- Hyperglobulinemia: Total protein > 7.8 g/dL
- α1-acid glycoprotein (AGP): > 1500 µg/mL highly suspicious
- Non-regenerative anemia: Common
- Lymphopenia, neutrophilia
- Liver enzyme elevation: ALT, ALP, total bilirubin elevated when jaundiced
Fluid Analysis (Wet Form)
- Character: High-protein (> 3.5 g/dL), low-cellularity exudate
- Color: Typically pale yellow to golden, viscous
- Rivalta test: Positive (a quick screen; negative largely rules out)
- Fluid PCR / IHC: FCoV detection in fluid is the closest to definitive diagnosis
Imaging
- Ultrasound: Ascites, pleural effusion, lymphadenopathy, mesenteric thickening, renal abnormalities
- MRI: Neurological FIP may show ventriculomegaly or meningeal enhancement
Important reminder: A positive "coronavirus antibody" result alone cannot diagnose FIP. It only means the cat has been exposed to feline coronavirus (which is very common). Definitive diagnosis requires combining clinical signs, blood work, fluid analysis, and imaging.
Treatment Breakthrough: GS-441524 Full Protocol
FIP was previously considered an almost universally fatal disease. According to the landmark study in the Journal of Feline Medicine and Surgery (Pedersen et al., 2019), the antiviral drug GS-441524 achieved 81% long-term remission in 31 cats with confirmed FIP. The larger Krentz et al. (2021) study confirmed similar success rates.
Reference Dosing (Always Follow Veterinary Prescription)
| Form | Injection Dose | Oral Dose | Duration |
|---|---|---|---|
| Wet (no neuro/ocular signs) | 6 mg/kg/day | 10 mg/kg/day | 84 days |
| Dry | 8 mg/kg/day | 12 mg/kg/day | 84 days |
| Ocular | 10 mg/kg/day | 15 mg/kg/day | 84 days |
| Neurological | 12-15 mg/kg/day | 15-20 mg/kg/day | 84 days |
In 2024, the U.S. FDA conditionally approved the first feline GS-441524 product (a Stokes Pharmacy compounded formulation of the Remdesivir prodrug). Many veterinary hospitals now offer the treatment, though costs are significant.
Monitoring During Treatment
- Weeks 1-2: Fever resolving, appetite returning, and increased activity are the earliest improvement signs
- Week 4: Recheck blood work (A:G, AGP, lymphocytes); body weight should be rising
- Week 8: Repeat blood work; most parameters should be near normal
- Week 12 (end of course): Full chemistry panel; imaging if indicated
- 12-week observation: Continue monitoring 12 weeks post-treatment to confirm no relapse
Common Side Effects
- Injection-site pain: Low pH causes notable discomfort during injection; pre-cooling or alternative formulations help
- Injection-site skin ulceration: Rare; rotate injection sites
- Liver enzyme elevation: Rare and usually transient
- Appetite changes: Usually improve as treatment progresses
Prognosis and Relapse Rate
- Overall remission rate: 75-85% across published studies (Pedersen 2019, Krentz 2021)
- Relapse rate: Roughly 5-10% within the 12-week post-treatment observation period; relapse cases can be re-treated
- Factors affecting success: Disease severity at start of treatment, presence of neurological involvement, comorbidities
- Bottom line: Earlier diagnosis and earlier treatment significantly improve outcomes
Preventive Measures
- Reduce infection risk in multi-cat environments: Maintain hygiene; keep litter boxes away from food bowls (fecal-oral transmission); follow the N+1 rule for litter boxes
- Reduce stress: Stress impairs immune control of the virus. See cat stress signs and relief
- Quarantine new cats: Isolate new cats for 2-3 weeks before introduction
- Keep the environment clean: FCoV survives in the environment for weeks but is susceptible to common disinfectants (e.g., 1:32 diluted bleach)
- Avoid overcrowding: High-density breeding environments are FIP risk hotspots
- Consider breed risk: Purebred households can review thebreed personality & health guide for genetic predispositions
Related Reading
- Cat upper respiratory infection — distinguish from early FIP signs
- Cat pancreatitis — another cause of persistent appetite loss
- Cat liver disease / fatty liver — differential for jaundice
- Cat vaccination schedule — supporting overall immunity
References
- Pedersen, N.C. (2009). A review of feline infectious peritonitis virus infection: 1963-2008. Journal of Feline Medicine and Surgery, 11(4), 225-258.
- Pedersen, N.C. et al. (2019). Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery, 21(4), 271-281.
- Tasker, S. (2018). Diagnosis of feline infectious peritonitis: Update on evidence supporting available tests. Journal of Feline Medicine and Surgery, 20(3), 228-243.
- Krentz, D. et al. (2021). Curing cats with feline infectious peritonitis with an oral multi-component drug containing GS-441524. Viruses, 13(11), 2228.
- Addie, D.D. et al. (2009). Feline infectious peritonitis. ABCD guidelines on prevention and management. Journal of Feline Medicine and Surgery, 11(7), 594-604.
- Cosaro, E. et al. (2023). Efficacy of oral remdesivir compared to GS-441524 for treatment of cats with naturally occurring effusive feline infectious peritonitis. Journal of Veterinary Internal Medicine, 37(6), 2099-2108.